The associated quiescence of inflammatory cell activation and several pathological intracellular signaling pathways demonstrates the critical role that mTOR plays and, along with evidence of mTOR activation and preserved transcriptomic signature in human specimen of MVP, provides an opportunity to test if clinical application of mTOR inhibition is feasible to modulate the progression of mitral valve disease. The gene discussed is MTOR; the disease is mitral valve disorder.